Organogenesis Holdings Inc. (ORGO) stock
ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/30
$0.80−0.01 (-0.86%)
Close on Nov 16, 2026Market cap $103.34MP/E –Yield –
Organogenesis ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Organogenesis's ebitda for the twelve months ending Jun 30, 2026 was -$19.93M. For fiscal 2025 it was $59.97M, up 386.0% from the year before.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.97M | +386.0% |
| FY2024 | Dec 31, 2024 | $12.34M | -46.3% |
| FY2023 | Dec 31, 2023 | $22.97M | -18.4% |
| FY2022 | Dec 31, 2022 | $28.15M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$47.32M | – |
| Q1 FY2026 | Mar 31, 2026 | -$64.72M | – |
| Q4 FY2025 | Dec 31, 2025 | $67.36M | +386.9% |
| Q3 FY2025 | Sep 30, 2025 | $24.76M | +152.3% |
| Q2 FY2025 | Jun 30, 2025 | -$8.84M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.30M | – |
| Q4 FY2024 | Dec 31, 2024 | $13.83M | +707.6% |
| Q3 FY2024 | Sep 30, 2024 | $9.81M | -7.4% |
| Q2 FY2024 | Jun 30, 2024 | -$10.53M | -187.9% |
| Q1 FY2024 | Mar 31, 2024 | -$780.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $1.71M | – |
| Q3 FY2023 | Sep 30, 2023 | $10.59M | – |
| Q2 FY2023 | Jun 30, 2023 | $11.97M | – |
See a number that looks wrong?